Association of SLCgenotype with tumor characteristics
In order to assess the correlation between SLC variants and the
clinic-pathological parameters, the patients were bifurcated based on
cancer stage (stage III versus stage IV), lymph node involvement
(Nx+N0+N1 versus N2+N3+N4), primary tumor extension (T3 versus T4), and
metastasis (positive versus negative) as shown in Supplementary
Table 5. 18.7% of lung cancer patients diagnosed with T4 tumor
extension carried mutant alleles for SLC19A1G80A genotype compared to 30.3% patients in T3
tumor extension (Table 5). A decreased odds of developing T4
was observed in mutant genotype (AA ) as compared to the patients
categorized in T3 tumor extension (AOR=0.42, 95% CI=0.2-0.89;
p=0.02 ). Similarly, when the comparison was made between the
patients with T3 and T4 size in SLCO1B1 T521C ,
a decreased odds towards lung carcinoma was observed in the heterozygous
(TC ) genotype of T4 as compared to the patients with T3 tumor
extension (AOR=0.29, 95% CI=0.11-0.77, p=0.01) . Using the
dominant model, combining the two risk genotypes (TC +CC ),
increased risk for lung cancer was not observed in T4 compared to
patients with T3 tumor extension (AOR=0.34, 95% CI=0.13-0.88;
p=0.02 ). Therefore, our results show that these
genotypes did not show any relationship with the tumor size and its
progression.